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Background: It is anticipated that demands on ambulatory HIV services will increase in coming years as a
consequence of the increased life expectancy of HIV patients on highly active anti-retroviral therapy (HAART).
Accurate cost data are needed to enable evidence based policy decisions be made about new models of service
delivery, new technologies and new medications.
Methods: A micro-costing study was carried out in an HIV outpatient clinic in a single regional centre in the south of
Ireland. The costs of individual appointment types were estimated based on staff grade and time. Hospital resources
used by HIV patients who attended the ambulatory care service in 2012 were identified and extracted from existing
hospital systems. Associations between patient characteristics and costs per patient month, in 2012 euros, were
examined using univariate and multivariate analyses.
Results: The average cost of providing ambulatory HIV care was found to be €973 (95% confidence interval
€938 - €1008) per patient month in 2012. Sensitivity analysis, varying the base-case staff time estimates by 20%
and diagnostic testing costs by 60%, estimated the average cost to vary from a low of €927 per patient month
to a high of €1019 per patient month. The vast majority of costs were due to the cost of HAART. Women were
found to have significantly higher HAART costs per patient month while patients over 50 years of age had significantly
lower HAART costs using multivariate analysis.
Conclusions: This study provides the estimated cost of ambulatory care in a regional HIV centre in Ireland. These data
are valuable for planning services at a local level, and the identification of patient factors, such as age and gender,
associated with resource use is of interest both nationally and internationally for the long-term planning of HIV care
provision.
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Highly active anti-retroviral therapy (HAART), available
since the mid-1990s, has transformed HIV infection into
a chronic disease [1]. Nowadays, with timely diagnosis
and engagement in care, people living with HIV can have
a life-expectancy that approaches that of the general
population [2,3]. However, HAART is not a curative
treatment and most newly diagnosed HIV patients face
the daunting prospect of decades of medication use and* Correspondence: aline.brennan@ucc.ie
1Department of Epidemiology and Public Health, University College Cork,
Cork, Ireland
Full list of author information is available at the end of the article
© 2015 Brennan et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.regular healthcare visits. It has also become apparent
that long term HIV infection and medication use is asso-
ciated with increased non-AIDS morbidity [1,4,5].
Since HIV testing began in the early 1980s over 6,600
people have been diagnosed with HIV in Ireland [6]. A
prevalence study of patients in care found 3,254 patients
accessed HIV care in Ireland in the 12-month period
from July 2009 to June 2010, with 25% over 45 years of
age [7]. Of these patients, 79% were on treatment and
94% of those had a viral load < 500 copies/ml [7], figures
that compare favourably with other developed countries
[8-10]. In Ireland, as in many other countries, policy
makers and clinicians are now faced with the challengel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of increasing demand and within on-going financial
constraints.
Data on the use and cost of services are needed to es-
timate the potential impact the changing HIV epidemi-
ology will have on the health service in Ireland, as well as
to support evidence based decisions about new models of
service delivery, technologies and medications [11]. It is
not generally appropriate to extrapolate costs from studies
in different countries due to variation in how health ser-
vices are provided and organised.
There are two general approaches to costing health-
care: top-down and bottom up. A top-down approach
estimates the cost of an individual service on average,
usually using routinely available data e. g. average per
diem costs. Top-down costing studies tend to be rela-
tively quick and easy to carry out, however they are also
less precise and cannot provide information on individ-
ual factors driving the costs [12]. A bottom-up approach
(micro-costing) generates a more precise estimate, but is
more difficult to perform. In micro-costing all resources
used are identified and then the unit costs of the re-
sources are multiplied by the quantities used [12]. Stud-
ies examining the differences between the cost estimates
produced by the two approaches have concluded that
bottom-up approaches are preferable for estimating cost
components which have a large impact on total costs
(e.g. labour, drugs), for services where there is wide
variation in costs between patients and for centres which
are integrated within a larger hospital compared to stand-
alone centres [13-15].
Existing data on the cost of outpatient care in Ireland
are limited. The national average cost of an outpatient
visit in Ireland was estimated to be €130 in 2011 using a
top-down methodology (National Casemix Programme,
date of communication 29/09/2013), however no infor-
mation is available on how this cost may vary across
specialties. A previous study looking specifically at the
pharmacoeconomics of HIV in Ireland carried out in
the early HAART era reported an average outpatient
cost of IR£493 per active patient month in 1999 which
would be equivalent to €1,184 in 2012 (inflated using
the Irish consumer price index for health) [16,17].
Ireland is currently in the process of restructuring its
healthcare funding system from one where hospitals are
funded based on historical levels of funding adjusted for
activity and patient mix to a prospective case based pay-
ment system (“Money Follows the Patient”) [18]. While it
is initially planned to implement this change for in-patient
and day-case activity, the new funding system will also en-
compass outpatient services [18]. It is proposed that prices
in the new system will be set initially with reference to
average prices, but with a view to implementing best prac-
tice prices on an incremental basis [18].The aim of this study was to estimate the total cost of
providing an outpatient HIV service in a single centre in
2012 from the health service provider perspective, and
to identify associated patient factors. We also compare
our results with other available sources of cost data.
Methods
Ethics
Ethical approval for this study was obtained from the
Clinical Research Ethics Committee of Cork University
Hospital.
Description of service
Cork University hospital (CUH) is one of the largest uni-
versity teaching hospitals in Ireland, and provides HIV
care for the counties of Cork, Kerry, Waterford, and
South Tipperary (covering approximately 20% of the
Irish population). The infectious disease (ID) department
holds two routine outpatient clinics specifically for HIV
patients: the main HIV clinic (“HIV clinic”) held once a
week and a joint ID-maternity clinic (“antenatal-HIV
clinic”) held once a month in the adjoining maternity
hospital. Patients attending the antenatal-HIV clinic
attend both obstetric and ID services during their
appointment.
Local clinical guidelines, based on international best-
practice [19-21], recommend that a CD4 count, viral
load (VL), full blood count (FBC) and biochemistry pa-
tient profile (renal, liver and bone profiles) are performed
every 3–4 months. Additional and/or more frequent test-
ing is recommended at initiation of care and at initiation
of HAART until suppression is achieved. Antenatal HIV
patients are monitored on a monthly basis.
Study participants
All patients who attended for HIV care in 2012 were
identified from a pre-existing clinical database which
contains the results of all viral load tests performed in
CUH. The database also contains basic demographic
and risk factor information on the patients who have
attended the public HIV clinic in CUH. Patients who
attended the public HIV clinic at least once in 2012
were eligible to be included in the study. Patients who
attended for private HIV outpatient care, who did not
attend any outpatient appointment in 2012, or who
routinely attended another HIV centre for their HIV
care were excluded.
For new patients to the clinic in 2012 (newly diag-
nosed or transferred from another clinic) the date of
their first appointment attended or admission was taken
as the start date of their care, for all other patients the start
date of care was 01/01/2012. Patients were considered to
be in care until 31/12/2012 if they used any hospital service
(outpatient/in-patient/emergency department) at least once
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who did not use any hospital service in the last 6 months of
2012 were manually checked, and these patients were cen-
sored at the date of their last scheduled appointment where
appropriate. Patients who had either a CD4 count < 350
cells/μl or an AIDS defining illness at the time of diagnosis
recorded in their medical notes were categorised as late
diagnoses.
Resource use
Information on the number and dates of all outpatient
appointments and diagnostic tests (laboratory, radiology
and cardiology) were extracted from the hospital infor-
mation system. Data on the total number of months of
each HAART regimen dispensed, as well as any relevant
start and/or stop dates, were extracted from pharmacy
patient files. The medical records of patients with no
pharmacy files were cross-checked to confirm the patient
did not receive HAART in 2012. In addition, information
on the number of doses of prophylactic antibiotics (azi-
thromycin, dapsone, sulfamethoxazole/trimethoprim and
pyrimethamine) dispensed to HIV patients was provided
by the hospital pharmacy. Diagnostic tests were linked
with patient appointments on the basis of matching test
and appointment dates. Radiology and cardiology tests,
which may not occur on the date of the outpatient ap-
pointment where the test was ordered, were linked with
the nearest previous outpatient appointment attended.
Costs
A micro-costing study was carried out to estimate the
cost of typical HIV outpatient appointments from the
service-provider perspective in 2012. Staff routinely
involved in providing or supporting the HIV clinic
(clerical, nursing, medical, phlebotomy, and pharmacy)
were interviewed to assess the HIV-clinic related tasks
performed by the staff member and the estimated
patient-facing and non patient-facing time involved.
Doctors and nurses self-recorded their patient-facing
times at six consecutive HIV clinics in March and
April 2013 (127/153 appointments timed). Pharmacy
staff self-recorded their HIV related patient-facing and
non patient-facing time for the month of April, 2013.
The accuracy of self-timed doctor patient-facing times
was confirmed by independent observation of approxi-
mately 50% of appointments. Average costs per ap-
pointment were then calculated based on estimated
time and salary of relevant staff using recommended
national guidelines [22].
Eight basic types of appointment were identified: 1) did
not attend scheduled outpatient appointment (DNA), pa-
tient was not on HAART at the time (“DNA, not on
HAART”); 2) DNA, patient was on HAART at the time
(“DNA, on HAART”); 3) attended the HIV-clinic, patientwas not on HAART at the time (“Attended HIV clinic, not
on HAART”); 4) attended the HIV-clinic, patient was on
HAART at the time (“Attended HIV clinic, on HAART”);
5) attended the antenatal HIV-clinic, patient was not on
HAART at the time (“Attended antenatal-HIV clinic, not
on HAART”); 6) attended the antenatal-HIV clinic, patient
was on HAART at the time (“Attended antenatal-HIV
clinic, on HAART”); 7) first attended appointment with
the ID service for HIV care, patient was not on HAART at
the time (“Baseline visit, not on HAART”); and 8) first
attended appointment with the ID service for HIV care,
patient was on HAART at the time (“Baseline visit, on
HAART”). Appointments were categorised as DNA if the
patient did not attend their scheduled appointment with-
out cancelling or rescheduling the appointment prior to
the start of the clinic they were due to attend. The cost of
a DNA appointment was estimated based on the same
non patient-facing administrative and pharmacy staff time
(where applicable) as attended appointments as well as
the time incurred rescheduling an appointment. In gen-
eral, a patient is considered lost to follow-up if they DNA
three consecutive appointments. For the antenatal-HIV
clinic appointments only the cost of the care delivered by
the ID team was included in the micro-costing.
Unit costs
The unit costs of diagnostic tests were obtained from
the finance department of the hospital and the National
Virus Reference Laboratory. The monthly costs of anti-
retroviral medications and prophylactic antibiotics were
provided by the hospital pharmacy. In Ireland, the price
of all prescribed drugs are set at a national level [23,24],
although individual hospitals can negotiate discounts
with wholesalers. The number of months of regimens
dispensed was used in the calculation of HAART costs
to allow for possible wastage due to regimen switching.
The hospital finance department also provided out-
patient costs per patient for comparison purposes from
a newly implemented activity based costing system.
These data were broken down into direct and indirect
costs by category (clinical salaries, nursing salaries, non-
clinical salaries, imaging, pathology etc.), but contained
little information on individual patient characteristics,
appointment types or diagnostic tests. Drug costs (with
the exception of a few very high cost drugs) were not
assigned at a patient level in the hospital activity based
costing system in 2012.
Data analysis
All information was entered into a Microsoft Access ®
database. Data were analysed using Microsoft Excel® and
STATA 12 (College Station, Texas). Weighted average
costs per patient month (ppm) were calculated to ac-
count for differences in patient lengths of follow-up.
Brennan et al. BMC Health Services Research  (2015) 15:139 Page 4 of 10Chi-squared tests were used to test for differences in
proportions. Logistic regression was used to estimate the
odds ratios of being treated with PI-based regimens
compared to NNRTI-based regimens in patients receiv-
ing a single type of regimen. Generalized linear models
were used to model costs ppm on HAART as they are
suitable for modelling cost data, which tend to be
skewed, without the need for transformation [25]. The
most appropriate family was chosen using the modified
Parks test, and the link was chosen using the Pearson
Correlation Test, the Pregibon Link Test and the modifiedTable 1 Unit costs (in 2012 euros) and frequency of appointm
common HAART regimens dispensed
Cost category Unit cost
Appointment type Staff cost per
appointment
DNA, not on HAART €12.68
DNA, on HAART €21.25
Attended HIV clinic, not on HAART €174.89
Attended HIV clinic, on HAART €194.88
Attended antenatal-HIV clinic, not on HAART €174.26
Attended antenatal-HIV clinic, on HAART €194.25
Baseline appointment, not on HAART €244.46
Baseline appointment, on HAART €264.45
Most common diagnostic tests Cost per test
CD4 €47.29
Viral load €92.94
Full Blood Count €6.79
Biochemistry profiles, weighted average cost €18.63
All other tests, weighted average cost €28.39
HAART regimens Cost per month
Efavirenz/Emtricitabine/Tenofovir (NNRTI-based regimen) €816.61
Emtricitabine/Tenofovir, Darunavir, Ritonavir (PI-based
regimen)
€1,097.51
Emtricitabine/Tenofovir, Atazanavir, Ritonavir (PI-based
regimen)
€1,084.84
Emtricitabine/Tenofovir, Lopinavir/Ritonavir (PI-based
regimen)
€1,148.79
Emtricitabine/Tenofovir, Nevirapine (NNRTI-based regimen) €747.98
Lamivudine/Zidovudine, Lopinavir/Ritonavir (PI-based
regimen)
€953.16
All other regimens, weighted average cost €923.70
Prophylactic antibiotics Cost per dose
Azithromycin €0.42
Sulfamethoxazole and trimethoprim €0.15
Dapsone €0.69
DNA, did not attend. “Staff cost” is the estimated total patient and non patient-facin
and cardiology tests. “Biochemistry profiles” refers to the number and weighted ave
“renal/bone”, “patient & lipid”, “patient & lipoprotein”, “urea, electrolytes & creatininHosmer and Lemeshow test to evaluate power links in in-
crements of 0.1 between 0 and 1 [26].
Unit costs
The unit costs of individual appointment types, common
diagnostic tests and regimen types are shown in Table 1.
Sensitivity analysis
To reflect the uncertainty in the estimates of staff time
and laboratory costs staff times were varied by 20% and
unit costs of diagnostic testing by 60% in a sensitivityent types, most common diagnostic tests and most
Resource use Source of cost data
Number of appointments
32 Micro-costing study
127 Micro-costing study
89 Micro-costing study
997 Micro-costing study
2 Micro-costing study
42 Micro-costing study
14 Micro-costing study
12 Micro-costing study
Number of tests
1013 Hospital Finance Dept
995 National Virus Reference
Laboratory
1036 Hospital Finance Dept
1042 Hospital Finance Dept
1262 Hospital Finance Dept
Number of months
dispensed
1515 Hospital pharmacy
864 Hospital pharmacy
389 Hospital pharmacy
99 Hospital pharmacy
75 Hospital pharmacy
53 Hospital pharmacy
327 Hospital pharmacy
Number of doses dispensed
330 Hospital Pharmacy
2047 Hospital Pharmacy
344 Hospital Pharmacy
g staff costs per appointment. Diagnostic tests includes laboratory, radiology
rage cost of the following biochemistry profiles: “patient”, “ward”, “bone”,
e” and “liver function tests”.
Table 2 Number and proportion of patients and
patient-months by patient characteristics
Characteristics Patients (%) Patient
months (%)
Patient type Existing patient 300 (91%) 3506 (95%)
New patients 26 (8%) 153 (4%)
Gender Male 192 (59%) 2148 (58%)
Female 134 (41%) 1511 (41%)
Age <50 years 284 (87%) 3172 (86%)
50+ years 42 (13%) 487 (13%)
Risk factor COHP 133 (41%) 1501 (41%)
Heterosexual 63 (19%) 721 (20%)
MSM/Bisexual 95 (29%) 1067 (29%)
IDU 18 (5%) 185 (5%)
Other 8 (2%) 96 (3%)
Unknown 9 (3%) 89 (2%)
Late diagnosis No 135 (41%) 1535 (42%)
Unknown 77 (23%) 840 (23%)
Yes 114 (35%) 1284 (35%)
Years since diagnosis 11+ years ago 95 (29%) 1107 (30%)
6-10 years ago 107 (33%) 1231 (34%)
1-5 years ago 100 (30%) 1140 (31%)
diagnosed in 2012 17 (5%) 105 (3%)
Lowest CD4 count
in 2012 (cells/μl)
500+ 168 (51%) 1894 (52%)
350-499 85 (26%) 973 (26%)
200-349 52 (16%) 581 (16%)
50-199 14 (4%) 146 (4%)
<50 7 (2%) 65 (2%)
Treatment and
viral load statusb
On HAART, suppressed 211 (64%) 2469 (67%)
On HAART, not
suppressed
37 (11%) 438 (12%)
On HAART, unable
to determine status
7 (2%) 75 (2%)
Started/Stopped
HAART
49 (15%) 440 (12%)
Not on HAART 22 (7%) 237 (6%)
Overall 326 (100%) 3659(100%)
COHP, person from a country of high prevalence with no other identifiable risk
factor available. IDU, current/former injecting drug user. Late diagnosis defined as
CD4 count < 350 cells/μl at diagnosis or AIDS defining illness at diagnosis. “On
HAART” means the patient was on HAART for the entire duration of the study,
“suppressed” was defined as all viral loads in 2012 < 50 copies/ml, with one test
result of 50–499 copies/ml allowed if previous and subsequent viral load results
were < 50 copies/ml.
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the approximate width of the confidence intervals of the
average doctor and nurse patient-facing times, while the
choice of 60% variation for diagnostic testing costs was
based on the difference in the weighted average test
costs calculated using alternative unit costs which were
available for a limited number of the tests.
Results
Study population
In total 326 patients (3659 patient months) were in-
cluded in this study. The characteristics of the patient
population can be seen in Table 2. The majority of pa-
tients (59%) were men and the average age of patients
was 40 years. Co-infection with hepatitis C virus (HCV)
was recorded for 7% of patients, Hepatitis B Virus
(HBV) in 2% of patients and both HBV and HCV in 1%
of patients. Eight percent (26/326) of patients were new
to the service in CUH in 2012, most of whom were
newly diagnosed in 2012 (n = 17). The CD4 profile of
patients improved with the number of years since diag-
nosis (Chi-squared test, P = 0.001).
Three patients died in 2012, two of these were con-
sidered HIV-related deaths both of which were of people
who were newly diagnosed with advanced illness (CD4 <
50 cells/μl) at the time of diagnosis.
Resource use
There were a total of 1315 HIV outpatient appointments
scheduled during 2012, with an average of 4.1 (median
4, range 1–15) scheduled appointments per patient and
3.6 (median 3, range 1–11) attended appointments per
patient. The frequencies of each type of appointment are
shown in Table 1.
In total 304 patients were on HAART for 3272 patient-
months, with 3322 months of HAART dispensed in total.
The majority of regimens dispensed consisted of a nucleo-
side reverse-transcriptase inhibitor (NRTI) backbone
combined with either a protease inhibitor (PI) or a non-
nucleoside reverse-transcriptase inhibitor (NNRTI). NNRTI-
based regimens were the most frequently dispensed
(164 patients, 1755 months dispensed) followed by PI-based
regimens (145 patients, 1477 months dispensed), with a
small number of patients being dispensed other regimens
types (10 patients, 90 months dispensed). Fifteen percent
(n = 45) of patients had more than one regimen pre-
scribed during the study period, most of which were
within the same class, although a small number of pa-
tients were prescribed regimens from different classes
during the study period (n = 15).
Total costs
The overall average cost of providing HIV outpatient
care was estimated to be €973 ppm in 2012 (median€940, interquartile range €938-€1008). As the cost of
HAART accounted for the majority (88%) of total costs,
varying the staff time estimates and unit costs of diag-
nostic testing did not result in substantial changes to the
average costs ppm in the sensitivity analysis, with total
costs ppm only varying by about 5% (Table 3). When
costs were stratified by whether the patient was on
Table 3 Average base-case cost, in 2012 euros, per patient month (ppm) and results of sensitivity analysis
Base case (95% CI) Lower estimate (95% CI) Upper estimate (95% CI)
Staff costs ppm (+/− 20%) €62 (€59-€65) €50 (€47-€52) €75 (€71-€78)
Diagnostic test costs ppm (+/−60%) €55 (€52-€59) €22 (€21-€23) €89 (€83-€94)
Total non-drug cost ppm €117 (€111-€124) €72 (€68-€76) €163 (€154-€172)
Total cost ppm (including drug costs) €973 (€938-€1,008) €927 (€893-€962) €1,019 (€983-€1,054)
Brennan et al. BMC Health Services Research  (2015) 15:139 Page 6 of 10HAART or not at the time, the average cost ppm not on
HAART was €107 (95% CI €65-€150) compared to
€1085 (95% CI €1060-€1111) ppm on HAART.
Patient factors
The mean total cost ppm generally differed little across
patient groups (Table 4). However, patients who were on
HAART for the duration of their time in the study and
were categorised as suppressed were found to have lower
average total monthly costs compared to those who were
not suppressed (mean €1043 ppm compared to €1189
ppm respectively).
HAART accounted for the vast majority of outpatient
costs. The unit cost of individual regimens varied from a
minimum of €552/month to a maximum of €1600/
month. Although NNRTI-based regimens tend to be less
expensive than PI-based regimens (the weighted average
cost of NNRTI-based regimens in this study was €809/
month compared to €1091/month for PI-based regimens),
there are many other factors apart from cost which influ-
ence regimen choice, including patient (e.g. demographic,
behavioural), clinical (resistance, adverse reactions,
co-morbidities) and health system factors (drugs avail-
able for prescription, clinician preferences). Significantly
lower proportions of new patients and newly diagnosed
patients received HAART in 2012 compared to exist-
ing and previously diagnosed patients (Chi-squared
test, P = 0.008 and P =0.017, respectively). While a signifi-
cantly higher proportion of those diagnosed late (i.e. with a
CD4 count <350 cells/μl or an AIDS defining illness at
diagnosis) received HAART (Chi-squared test, P = 0.003).
On multivariate logistic regression of these three factors
late diagnosis was the only factor that remained significant
with an odds ratio (OR) of 15.5 (95% CI 2–120). Logistic
regression of regimen type (analysis restricted to patients
only prescribed PI-based regimens or only prescribed
NNRTI-based regimens, n = 283) found women were
significantly more likely to be prescribed a PI-based
regimen (OR 6.6, 95% CI 3.3-13.2, p < 0.001), while
those over 50 years were less likely to be prescribed a
PI-based regimen (OR 0.34, 95% CI 0.14-0.85, p = 0.022)
when adjusted for risk factor, patient type, years since
diagnosis, CD4 < 350 cells/μl and late diagnosis.
The results of multivariate analysis of non-HAART,
HAART and total costs ppm on HAART are shown in
Table 5.Comparisons of total costs with other sources of cost
data
Patient level costs for the HIV patients included in the
micro-costing study were provided by the hospital fi-
nance department. The data are activity based costing
data, the cost components of which are generated using
a top-down methodology. The total number of HIV out-
patient appointments in the finance dataset was very
similar to the total scheduled number of appointments
from the utilisation study (1310 vs 1315) which would
be expected given that the finance costs are based on in-
formation recorded in the same hospital information
system as the utilisation data were extracted from. As
the costs of most drugs were not assigned at a patient
level in this system in 2012, it was not appropriate to
compare drug costs, however the estimated non-drug
cost ppm based on the hospital activity-based cost data
was €63 ppm (95% CI €59-€67) compared to €117 (95%
CI €111-€124) in the micro-costing study. Use of the na-
tional average outpatient appointment cost (€130.56 in
2012) would have resulted in an even lower estimate of
€47 ppm (95% CI €44-€49 ppm). While our estimate is
greater than the estimates generated using routine data,
the estimated total cost (€973 ppm) is about 20% lower
than the IR£493 per active patient month in 1999 reported
by a previous micro-costing study (equivalent to €1,184 in
2012). Although that study was carried out in the early
HAART era and the patient population was quite different
to the patient population in this study [16].
Discussion
This study reports the results of a bottom-up costing
study of routine HIV outpatient care performed in a re-
gional referral centre in the south of Ireland. The total
estimated cost of the service in 2012 was €973 ppm,
nearly 90% of which was due to the cost of HAART.
While it is difficult to compare costs across countries,
HAART is reported to account for 60%-80% of the total
cost of HIV care (including inpatient care) in many stud-
ies in developed countries [27-33].
Despite its cost, HAART is considered a very cost-
effective treatment [19,34], and also has the important
population-level benefit of reducing onward transmis-
sion [35]. HAART also offers the greatest opportunity
for reducing costs, for example, in this study the total
non-drug spend would have to be reduced by over 35%
Table 4 Costs per patient month (ppm) by patient subgroup
N Mean drug cost ppm
(95% CI)
Mean non-drug costs ppm
(95% CI)
Mean total cost ppm
(95% CI)
Patient type
Existing patient 300 €863 (€829-€897) €112 (€107-€116) €975 (€940-€1,010)
New patients 26 €678 (€503-€853) €253 (€206-€300) €931 (€732-€1,130)
Gender
Male 192 €844 (€805-€882) €117 (€109-€124) €960 (€921-€999)
Female 134 €873 (€812-€934) €118 (€108-€129) €991 (€927-€1,055)
Age group
<50 years 284 €859 (€821-€897) €121 (€114-€128) €980 (€941-€1,019)
50+ years 42 €833 (€773-€894) €94 (€85-€104) €928 (€871-€984)
Risk factor
COHP 133 €878 (€826-€931) €117 (€106-€127) €995 (€940-€1,050)
MSM/Bisexual 95 €826 (€769-€884) €122 (€110-€134) €948 (€889-€1,007)
Heterosexual 63 €835 (€745-€925) €113 (€101-€125) €948 (€856-€1,041)
IDU 18 €931 (€834-€1,027) €124 (€103-€144) €1,054 (€942-€1,166)
Other 8 €982 (€733-€1,231) €92 (€59-€125) €1,075 (€817-€1,332)
Unknown 9 €697 (€383-€1,012) €125 (€92-€159) €823 (€514-€1,132)
Late diagnosis
No 135 €810 (€748-€871) €120 (€111-€130) €930 (€867-€993)
Unknown 77 €868 (€797-€939) €115 (€103-€126) €983 (€908-€1,058)
Yes 114 €902 (€862-€942) €116 (€104-€127) €1,018 (€974-€1,062)
Years since diagnosis
11+ years ago 95 €879 (€830-€929) €102 (€95-€108) €981 (€930-€1,032)
6-10 years ago 107 €890 (€833-€947) €107 (€99-€115) €997 (€938-€1,056)
1-5 years ago 100 €831 (€762-€899) €130 (€119-€141) €961 (€889-€1,033)
diagnosed in 2012 17 €581 (€349-€812) €275 (€208-€342) €855 (€582-€1,128)
Lowest CD4 count in 2012 (cells/μl)
500+ 168 €888 (€844-€932) €104 (€98-€110) €993 (€947-€1,038)
350-499 85 €807 (€734-€879) €120 (€108-€132) €927 (€852-€1,002)
200-349 52 €830 (€735-€925) €129 (€114-€145) €960 (€861-€1,058)
50-199 14 €839 (€725-€953) €179 (€115-€244) €1,018 (€873-€1,164)
<50 7 €903 (€706-€1,100) €218 (€118-€319) €1,121 (€842-€1,401)
Treatment and viral load status
On HAART, suppressed 211 €939 (€915-€964) €104 (€100-€109) €1,043 (€1,017-€1,069)
On HAART, not suppressed 37 €1035 (€987-€1,083) €154 (€134-€175) €1,189 (€1,133-€1,245)
On HAART, undetermined status 7 €914 (€776-€1,052) €84 (€55-€113) €998 (€845-€1,151)
Started/Stopped HAART 49 €660 (€578-€742) €169 (€141-€197) €829 (€733-€924)
Not on HAART 22 - €103 (€79-€128) €103 (€79-€128)
Overall 326 €856 (€822-€889) €117 (€111-€124) €973 (€938-€1,008)
COHP, person from a country of high prevalence with no other identifiable risk factor available. IDU, current/former injecting drug user. Late diagnosis defined as
CD4 count < 350 cells/μl at diagnosis or AIDS defining illness at diagnosis. “On HAART” means the patient was on HAART for the entire duration of the study,
“suppressed” was defined as all viral loads in 2012 < 50 copies/ml, with one test result of 50–499 copies/ml allowed if previous and subsequent viral load results
were < 50 copies/ml.
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reduction in HAART costs. Possible strategies for redu-
cing HAART costs do exist, such as increased use ofgeneric drugs or less expensive regimens where available
and appropriate [36-38], though efforts to reduce drug
spend should not come at the cost of increased risk of
Table 5 Results of multivariate analysis of non-HAART,
HAART and total costs ppm on HAART
Non HAART cost
ppm on HAART
Coefficient1
HAART cost ppm
Coefficient2
Total cost ppm
on HAART
Coefficient2
New patient −6.555* −0.03 −0.004
Female 1.464 0.138* 0.139*
Age 50+ years −3.113* −0.101* −0.117*
Risk factor
COHP
MSM 1.308 0.033 0.037
Heterosexual 0.32 0.054 0.054
Other/unknown −0.737 0.05 0.054
Late diagnosis
No ref ref ref
Unknown −0.354 −0.012 −0.015
Yes −0.515 −0.035 −0.04
Years since
diagnosis
11+ years ago ref ref ref
6-10 years ago −0.267 0.053 0.05
1-5 years ago 1.825 0.041 0.059
diagnosed in 2012 4.504 0.078 0.128
Min CD4 < 350
cells/μl
3.432* 0.02 0.054
On HAART, not
suppressed/other
2.051 0.059 0.089*
Constant 31.314 3.896 4.026
1) Generalised linear model with Inverse Gaussian family and link power 0.5. 2)
Generalised linear model, with Gaussian family and link power 0.2. * p < 0.05. PPM,
per patient month. COHP, person from a country of high prevalence with no other
identifiable risk factor available. IDU, current/former injecting drug user. Late
diagnosis defined as CD4 count < 350 cells/μl at diagnosis or AIDS defining illness at
diagnosis. “On HAART” means the patient was on HAART for the entire duration of
the study, “suppressed” was defined as all viral loads in 2012 < 50 copies/ml, with
one test result of 50–499 copies/ml allowed if previous and subsequent viral load
results were < 50 copies/ml. “On HAART, other” includes patients on HAART who
were not suppressed or had undetermined status and those who started/stopped
HAART in 2012.
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regimen choice is influenced by patient factors, such as
age, gender and risk factor, variation in costs between
centres at a national level is likely to be a reflection of
differences in patient populations, although clinician
preference may also play a role. With time, as more pa-
tients switch onto newer treatments, the drug costs are
likely to increase unless savings can be made through in-
creased use of generic drugs [36-38] or other rationalisa-
tion measures. In any case, further research is warranted
into the patient and healthcare factors influencing regi-
men choice, such as the acceptability and potential im-
pact of a preferred medicine scheme.
The most important factor on multivariate analysis
which influenced total costs ppm on HAART was gender,with women being 15% more expensive than men. It was
also interesting to note that patients over 50 years of age
had significantly reduced costs ppm on HAART. This was
due to a combination of older patients tending to be on
less expensive NNRTI-based regimens, as well as having
fewer scheduled appointments (0.26 ppm compared to
0.37 ppm, p < 0.001). The lower appointment rate in older
patients contrasts with previous studies which have found
older patients have higher utilisation rates [39], and may
be a reflection of the particular characteristics of this
patient cohort. Late diagnosis has been reported in the
literature to be associated with sustained increased
healthcare costs [40], in this study there was some evi-
dence that those diagnosed late had higher mean out-
patient costs (Table 4), however the differences were
not significant using multivariate analysis.
There are several limitations to this study. The data
collection was restricted to one year, so changes over
time cannot be examined. The usage and cost of other
services (inpatient, emergency, and non-ID outpatient
care) were not included in this analysis. While the ma-
jority of HIV-related care is now provided on an out-
patient basis by the ID team, a small minority of patients
use a substantial amount of other services [41]. Newly
diagnosed patients with low CD4 counts in particular
can have very complex care needs, in this study the in-
patient costs of two newly diagnosed patients who were
diagnosed late and subsequently died were not captured
by this micro-costing study. CUH has a smaller propor-
tion of injecting drug users than the national HIV pa-
tient population (5% vs 21% ), however the population
served is similar in terms of age, gender, CD4 count and
viral load to the national cohort in care [7]. Diagnostic
tests were linked to specific outpatient appointments on
date and mis-matching may have occurred which could
have led to either an under- or over-estimate of the diag-
nostic testing ordered by the HIV clinic. Private patients
were not included in the study. While private patients
do not attend the public outpatient clinic so would not
generate appointment costs, the health service provider
may incur costs as a result of diagnostic tests and/or
HAART. The additional cost of obstetric care for HIV
patients (i.e. additional to the three consultant visits that
antenatal patients are routinely entitled to [42]) was not
included in the cost estimates. As the numbers of
women attending antenatal care was very small in this
study it was not possible to investigate this fully, but to
give an indication of the scale of the possible additional
costs the average number of antenatal-HIV appoint-
ments attended in this study was 3.2 per woman. This
study also does not include the cost of medications pre-
scribed to HIV patients other than HAART and prophy-
lactic antibiotics, as these are dispensed outside the
hospital setting, while the total cost of vaccines and
Brennan et al. BMC Health Services Research  (2015) 15:139 Page 9 of 10tuberculin dispensed to the HIV clinic was available but
could not be assigned at a patient level. The total esti-
mated cost of vaccines and tuberculin in 2012 was
€3,734 (including consumables) and even though this is
probably an underestimate as patients may be vaccinated
in other healthcare settings, overall it is likely to account
for a relatively small proportion of the total costs of am-
bulatory HIV care in this centre.
Conclusions
Accurate cost data are essential for ensuring HIV ser-
vices are effective, efficient, and equitable and cost infor-
mation should be used to guide policy, planning and
implementation [11]. This is particularly pertinent in the
current situation in Ireland, as healthcare funding is
undergoing restructuring. We have found that HIV out-
patient costs were substantially underestimated by rou-
tine hospital cost data, and we feel that this information
will be vital for the development of realistic setting of
HIV outpatient appointment prices in the new funding
system. In addition, as demands on the service increase
due to greater numbers of patients and more complex
care these cost data will be available for cost-effectiveness
evaluations of new drugs, technologies and models of
care.
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